DC551040 是一种口服有效且选择性的赖氨酸去甲基化酶 1 (LSD1) 抑制剂,对人源 LSD1 的 IC50 为 2.14 nM,其通过与 Trp552 形成 π-π 堆积作用、与 Phe538 形成极性相互作用并与 FAD 形成共价加合物来结合 LSD1,破坏 LSD1-GFI1B-CoREST 复合物,诱导 H3K4me2 积累、细胞凋亡 (apoptosis) 与分化,激活 STAT5、NF-κB、AKT 及 IL6-STAT3 通路并上调 IL6 表达,可用于急性髓系白血病的相关研究。
产品编号: MS-Z28112 CAS No.: 2133291-32-2 分子式: C22H32FN3O2 分子量: 389.51
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

DC551040 是一种口服有效且选择性的赖氨酸去甲基化酶 1 (LSD1) 抑制剂,对人源 LSD1 的 IC50 为 2.14 nM,其通过与 Trp552 形成 π-π 堆积作用、与 Phe538 形成极性相互作用并与 FAD 形成共价加合物来结合 LSD1,破坏 LSD1-GFI1B-CoREST 复合物,诱导 H3K4me2 积累、细胞凋亡 (apoptosis) 与分化,激活 STAT5、NF-κB、AKT 及 IL6-STAT3 通路并上调 IL6 表达,可用于急性髓系白血病的相关研究。

生物实验数据

生物活性 DC551040 is an orally active and selective lysine demethylase 1 (LSD1) inhibitor with an IC50 of 2.14 nM against human LSD1 that binds LSD1 by forming π-π stacking with Trp552, polar interactions with Phe538, and a covalent adduct with FAD, disrupts the LSD1-GFI1B-CoREST complex, induces H3K4me2 accumulation, apoptosis, and differentiation, activates STAT5, NF-κB, AKT, and IL6-STAT3 pathways, and upregulates IL6 expression, and can be used for research related to acute myeloid leukemia.
IC50 & Target LSD1:2.14 nM
体外研究
(In Vitro)

DC551040 (孵育 1 小时) 可强效抑制重组人源 LSD1 的酶活性,其 IC50 为 2.14 nM。
DC551040 对重组人源 LSD1 表现出相较于重组人源 LSD2、MAO-A 及 MAO-B 的优异选择性。
DC551040 (300 nM;1 小时预处理) 可不可逆地抑制重组人源 LSD1,因为稀释后酶活性无法恢复。
DC551040 (50-250 nM;24 小时) 可破坏 MV-4-11 急性髓系白血病 (AML) 细胞中的 LSD1-GFI1B-CoREST 复合物。
DC551040 (7 天) 可强效抑制 MV-4-11、Kasumi-1 和 HL-60 急性髓系白血病 (AML) 细胞系的增殖,其 IC50 值分别为 79.51 nM、25.77 nM 和 40.35 nM,同时对非 AML 血液癌细胞系仅表现出微弱活性。
DC551040 (7 天) 可抑制 AML 患者来源细胞的增殖,在 4 个样本中的 IC50 值范围为 0.68 nM 至 4157 nM。
DC551040 (0.5-4 μM;72 小时) 可在 MV-4-11 急性髓系白血病 (AML) 细胞中诱导剂量依赖性凋亡,凋亡率分别为 7.16%、7.78% 和 10.76%。
DC551040 (24 小时) 可诱导 MV-4-11 急性髓系白血病 (AML) 细胞分化,表现为 CD86 表达升高及特征性形态学改变。
DC551040 (0.1-2 μM;1-7 天) 可呈剂量依赖性上调 MV-4-11 急性髓系白血病 (AML) 细胞中的 H3K4me2 水平。
DC551040 对正常外周血单个核细胞毒性较低,其 IC50 大于 10 μM。
DC551040 (1-5 μM;12 小时) 可上调 MV-4-11 急性髓系白血病 (AML) 细胞中 STAT3 的磷酸化水平。
DC551040 (0.3-3 μM;48 小时) 可呈剂量依赖性上调 MOLM-13、MV-4-11 和 HL-60 急性髓系白血病 (AML) 细胞中 IL6、MYC、CCL5 及 VEGFA 的 mRNA 表达。
DC551040 (0.23-5000 nM;10 天) 与 HHT (MS-Y17803) 可协同抑制 MOLM-13、MV-4-11、HL-60、Kasumi-1 急性髓系白血病 (AML) 细胞系以及 AML 患者来源细胞的增殖,联合处理 10 天后可产生较高的协同评分 (ZIP >10,Bliss score 21.25)。
DC551040 (0.5 μM;24 小时) 联合 HHT 可显著提高经 24 h 处理后的 MV-4-11 急性髓系白血病 (AML) 细胞中 Caspase 3/7 的活性。

Western Blot Analysis

Cell Line: MV-4-11 AML cells
Concentration: 50 nM; 250 nM
Incubation Time: 24 h
Result: Disrupted the association between LSD1 and GFI1B, as shown by reduced co-immunoprecipitation of LSD1 with GFI1B.

Apoptosis Analysis

Cell Line: MV-4-11 AML cells
Concentration: 0.5 μM; 2 μM; 4 μM
Incubation Time: 72 h
Result: Induced apoptosis in a dose-dependent manner: 7.16% apoptosis at 0.5 μM, 7.78% at 2 μM, and 10.76% at 4 μM, compared to 4.07% in the DMSO control.

Western Blot Analysis

Cell Line: MV-4-11 AML cells
Concentration: 0.1 μM; 0.5 μM; 2 μM
Incubation Time: 1 day, 3 days, 5 days, 7 days
Result: Increased H3K4me2 levels in a dose-dependent manner across all time points: at 1 day, relative ratios were 1.01 at 0.1 μM, 1.25 at 0.5 μM, 1.25 at 2 μM; at 3 days, 1.20 at 0.1 μM, 1.67 at 0.5 μM, 1.51 at 2 μM; at 5 days, 1.22 at 0.1 μM, 1.52 at 0.5 μM, 1.53 at 2 μM; at 7 days, 1.11 at 0.1 μM, 1.25 at 0.5 μM, 1.35 at 2 μM.

Western Blot Analysis

Cell Line: MV-4-11 AML cells
Concentration: 1 μM; 5 μM
Incubation Time: 12 h
Result: Upregulated phosphorylation of STAT3.

Real Time qPCR

Cell Line: MOLM-13, MV-4-11, HL-60 AML cells
Concentration: 0.3 μM; 1 μM; 3 μM
Incubation Time: 48 h
Result: Dose-dependently upregulated IL6 mRNA expression in MOLM-13, MV-4-11, and HL-60 cells.
Dose-dependently upregulated MYC, CCL5, and VEGFA mRNA expression in MOLM-13 cells.

Apoptosis Analysis

Cell Line: MV-4-11 AML cells
Concentration: 0.5 μM; 0.5 μM plus 5 nM HHT
Incubation Time: 24 h
Result: Significantly increased Caspase 3/7 activity (to ~3-fold) compared to either monotherapy (both ~1.5-fold) or DMSO control (~1-fold).
体内研究
(In Vivo)

DC551040 (0.5-2 mg/kg;口服;每日;17 天) 在 Kasumi-1 异种移植小鼠中表现出剂量依赖性抗肿瘤活性,在每日 2 mg/kg 口服给药条件下达到 86.99% 的最高 TGI。
DC551040 (5-10 mg/kg;口服;每日一次;连续 22 天) 在 MV-4-11 异种移植小鼠中发挥剂量依赖性抗肿瘤活性,在 10 mg/kg 每日口服给药条件下达到 61.23% 的 TGI,并可诱导分化标志物 CD86 呈剂量依赖性上调。
DC551040 (0.5-4 mg/kg;口服;每日一次;连续 21 天) 可呈剂量依赖性延长播散性 MV-4-11 急性髓系白血病小鼠的生存期。
DC551040 (1 mg/kg;口服;每日一次;连续 28 天) 与 HHT 协同作用,可显著延长播散性 MV-4-11 AML 小鼠的生存期。
DC551040 (2 mg/kg;口服;每日一次;连续 21 天) 可降低 AML 患者来源异种移植小鼠的残留白血病负荷,并与 HHT 协同增强该效应。
DC551040 (2 mg/kg;口服;每日;持续 21 天) 可在 MV-4-11 异种移植瘤中诱导免疫和炎症通路的动态激活,同时引发时间依赖性的代谢重编程。

Animal Model: Nu/Nu nude mice (subcutaneously inoculated in the right flank with 5 × 106 Kasumi-1 cells for a subcutaneous xenograft model)
Dosage: 0.5 mg/kg; 1 mg/kg; 2 mg/kg
Administration: p.o.; daily; 17 days
Result: Demonstrated dose-dependent tumor suppressive activity, with corresponding tumor growth inhibition (TGI) rates of 48.82%, 60.81%, and 86.99%, respectively.
Exhibited superior antitumor effect at 2 mg/kg compared to GSK2879552 (MS-F88693) at 2 mg/kg.
Animal Model: Nu/Nu nude mice (subcutaneously inoculated in the right flank with 5 × 106 MV-4-11 cells for a subcutaneous xenograft model)
Dosage: 5 mg/kg; 10 mg/kg
Administration: p.o.; daily; 22 days
Result: Demonstrated dose-dependent tumor suppressive activity, with TGI rates of 41.08% and 61.23%, respectively.
Showed significantly better tumor inhibitory effect at 10 mg/kg compared to GSK2879552 at 10 mg/kg.
Caused dose-dependent upregulation of CD86 positivity in tumor tissues, with higher CD86 expression observed at 10 mg/kg compared to 5 mg/kg.
Animal Model: B-NDG mice (received tail
vein injection of 1 × 107 MV-4-11 cells for intravenous engraft-
ment)
Dosage: 0.5 mg/kg; 2 mg/kg; 4 mg/kg
Administration: p.o.; daily; 21 days
Result: Demonstrated dose-dependent improvement in mouse survival, with longer survival observed at higher doses compared to vehicle control.
Animal Model: B-NDG mice (received tail
vein injection of 1 × 107 MV-4-11 cells for intravenous engraft-
ment)
Dosage: 1 mg/kg
Administration: p.o.; daily; 28 days
Result: Combination treatment with homoharringtonine (HHT, 0.5 mg/kg) significantly extended median mouse survival to 57.5 days, compared to 47.5 days for monotherapy and 48.5 days for HHT monotherapy.
Animal Model: B-NDG mice (received tail
vein injection of 1 × 107 primary AML cells for intravenous engraft-
ment)
Dosage: 2 mg/kg
Administration: p.o.; daily; 21 days
Result: Significantly reduced the proportion of human CD33+ cells in mouse bone marrow compared to vehicle control.
Combination treatment with HHT (0.5 mg/kg) produced a further significant reduction in CD33+ cells, demonstrating a synergistic effect.
Animal Model: Nu/Nu nude mice (subcutaneously inoculated in the right flank with 5 × 106 MV-4-11 cells for a subcutaneous xenograft model)
Dosage: 2 mg/kg
Administration: p.o.; daily; up to 21 days
Result: Induced dynamic changes in protein and gene expression: 233, 276, and 256 proteins were significantly changed at 3, 7, and 21 days, respectively (|log2(fold change)| > 0.585 and p < 0.05).
Activated immune and inflammation-related pathways (including IL6-JAK-STAT3, IL2-STAT5, interferon-γ response) across all time points.
Caused time-dependent alterations in metabolic pathways: oxidative phosphorylation was weakened at 21 days, carbon metabolism and glycolysis/gluconeogenesis were enhanced at 21 days, fatty acid metabolism decreased at 3 days then increased at 7 and 21 days.

化学信息

分子量 389.51
分子式 C22H32FN3O2
CAS No. 2133291-32-2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础